Efficient designs for phase II oncology trials with ordinal outcome

Statistics and its Interface

Volumn 5, Issue 4, 2012, Pages 463-469

  Ivanova, Anastasia ^a,b   Monaco, Jane ^a   Stinchcombe, Thomas ^b  

^a University of North Carolina at Chapel Hill   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Ordinal outcome; Phase II trial; Simon's design; Tumor response

Indexed keywords

EID: 84876333221     PISSN: 19387989     EISSN: 19387997     Source Type: Journal    
DOI: 10.4310/SII.2012.v5.n4.a9     Document Type: Article

References (20)

1. Abrey, L. E., Olson, J. D., Raizer, J. J., Mack, M., Rodavitch, A., Boutros, D. Y. and Malkin, M. G. (2001). A phase II trial of temozolomide for patients with recurrent or progressive brain metastases. Journal of Neuro-Oncology 53 259-265.
2. Cohen, E. E. W., Rosen, F., Stadler, W. M., Recant, W., Stenson, K., Huo, D. and Vokes, E. E. (2003). Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. Journal of Clinical Oncology 21 1980-1987.
3. Eisenhauer, E. A, Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., Rubinstein, L., Shankar, L., Dodd, L., Kaplan, R., Lacombe, D. and Verweij, J. (2009). New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). European Journal of Cancer 45 228-247.
4. Erasmus, J. J., Gladish, G. W., Broemeling, L., Sabloff, B. S., Truong, M. T., Herbst, R. S. and Munden, R. F. (2003). Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: Implications for assessment of tumor response. Journal of Clinical Oncology 21 2574-2582.
5. Fleming, T. R. (1982). One-sample multiple testing procedure for phase II clinical trials. Biometrics 38 143-151.
6. Gutierrez, M. E., Kummar, S. and Giaccone, G. (2009). Next generation oncology drug development: Opportunities and challenges. Nature Reviews Clinical Oncology 6 259-265.
7. Ivanova, A., Qaqish, B. F. and Schell, M. J. (2005). Continuous toxicity monitoring in phase I trials in oncology. Biometrics 61 540-545. MR2140926
8. Jung, S. H., Lee, T., Kim, K. M. and George, S. L. (2004). Admissible two-stage designs for phase II cancer clinical trials. Statistics in Medicine 23 561-569.
9. Kim, E. S., Hirsh, V., Mok, T., Socinski, M. A., Gervais, R., Wu, Y. L., Li, L. Y., Watkins, C. L., Sellers, M. V., Lowe, E. S., Sun, Y., Liao, M. L., Osterlind, K., Reck, M., Armour, A. A., Shepherd, F. A., Lippman, S. M. and Douillard, J. Y. (2008). Gefitinib Versus Docetaxel in previously treated nonsmall- cell lung cancer: A randomised phase III trial. Lancet 372 1809-1818.
10. Lin, X., Allred, R. and Andrews, G. (2008). A two-stage phase II trial design utilizing both primary and secondary endpoints. Pharmaceutical Statistics 7 88-92.
11. Lin, S. and Chen, T. (1998). Optimal two-stage designs for phase II trials with differentiation of complete and partial responses. Communications in Statistics - Theory and Methods 29 923-940.
12. Lu, Y., Jin, H. and Lamborn, K. R. (2005). A design of phase II cancer trials using total and complete response endpoints. Statistics in Medicine 24 3155-3170. MR2209049
13. Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., Louis, D. N., Christiani, D. C., Settleman, J. and Haber, D. A. (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to Gefitinib. New England Journal of Medicine 350 2129-2139.
14. Marcus, R., Peritz, E. and Gabriel, K. R. (1976). On closed testing procedures with special reference to ordered analysis of variance. Biometrika 63 655-660. MR0468056
15. Oxnard, G. R., Zhao, B., Sima, C. S., Ginsberg, M. S., James, L. P., Lefkowitz, R.A., Guo, P.,Kris, M. G., Schwartz, L. H. and Riely, G. J. (2011). Variability of Lung Tumor measurements on repeat computed tomography scans taken within 15 minutes. Journal of Clinical Oncology 29 3114-3119.
16. Paez, J. G., Janne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., Naoki, K., Sasaki, H., Fujii, Y., Eck, Sellers, W. R., Johnson, B. E. and Meyerson, M. (2004). EGFR mutations in lung cancer: Correlation with clinical response to Gefitinib therapy. Science 304 1497-1500.
17. Panageas, K. (2002). An optimal two-stage phase II design utilizing complete and partial response information separately. Controlled Clinical Trials 23 367-379.
18. Shepherd, F. A., Dancey, J., Ramlau, R., Mattson, K., Gralla, R., O'Rourke, M., Levitan, N., Gressot, L., Vincent, M., Burkes, R., Coughlin, S., Kim, Y. and Berille, J. (2000). Prospective randomized trial of Docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. Journal Clinical Oncology 18 2095-2103.
19. Shepherd, F. A., Pereira, J. R., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., van Kooten, M., Dediu, M., Findlay, B., Tu, D., Johnston, D., Bezjak, A., Clark, G., Santabarbara, P. and Seymour, L. (2005). Erlotinib in previously treated non-small-cell lung cancer. New England Journal of Medicine 353 123-132.
20. Simon, R. (1989). Optimal two-stage designs for phase II clinical trials. Controlled Clinical Trials 10 1-10.